The current financial score of Axsome Therapeutics Inc is 7.48. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 259.69M, representing a year-over-year increase of 51.87%, while its net profit experienced a year-over-year increase of 72.73%.
The current valuation score of Axsome Therapeutics Inc is 9.55. Its current P/E ratio is -34.83, which is -70.75% below the recent high of -10.19 and -96.59% above the recent low of -68.46.
The current earnings forecast score of Axsome Therapeutics Inc is 8.64. The average price target is 267.11, with a high of 315.00 and a low of 220.00.
The current price momentum score of Axsome Therapeutics Inc is 4.77. Currently, the stock price is trading between the resistance level at 159.40 and the support level at 111.60, making it suitable for range-bound swing trading.
The current institutional shareholding score of Axsome Therapeutics Inc is 7.00. The latest institutional shareholding proportion is 76.62%, representing a quarter-over-quarter decrease of 10.29%.
The current risk assessment score of Axsome Therapeutics Inc is 7.16. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.